Optimal topical drug for COVID-19 therapy in children
Infektsionnye Bolezni
; 20(2):41-46, 2022.
Article
in Russian
| EMBASE | ID: covidwho-2044285
ABSTRACT
Objective. To evaluate the efficacy of a benzydamine-containing drug in children with COVID-19. Patients and methods. This observational randomized study included 88 children with confirmed mild or moderate COVID-19. The experimental group comprised 44 children who received drugs containing benzydamine, whereas the control group comprised 44 children who received other local treatments. The groups were matched for age, sex, disease severity, main manifestations, and systemic therapy received. Results. Children in the experimental group demonstrated faster recovery than those from the control group (after 6.20 ± 2.93 days vs 7.36 ± 3.17 days, respectively;р < 0.05). Virus elimination occurred earlier in children receiving benzydamine than in controls (3.93 ± 2.48 days vs 5.27 ± 3.64 days, respectively;р < 0.05. Benzydamine significantly reduced the duration of pharyngeal hyperemia (by 2.29%), sore throat (by 1.77 days;р < 0.05), and fever (by 0.93 days;р < 0.05) compared to other local treatments. Conclusion. Benzydamine significantly increases the efficacy of COVID-19 treatment.
antiviral therapy; article; child; controlled study; coronavirus disease 2019; female; fever; human; hyperemia; local therapy; major clinical study; male; nonhuman; pharynx; randomized controlled trial; Severe acute respiratory syndrome coronavirus 2; sore throat; systemic therapy; topical drug administration; benzydamine
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Russian
Journal:
Infektsionnye Bolezni
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS